FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334985384> ?p ?o ?g. }

• W2334985384 endingPage "344" @default.
• W2334985384 startingPage "336" @default.
• W2334985384 abstract "Background: The phase 3 studies of telaprevir (T) in combination with peginterferon α-2a and ribavirin (PR) in treatment-naive genotype 1 chronic hepatitis C virus-infected patients (ADVANCE/ILLUMINATE) were not designed a priori to assess the effect of race and ethnicity on treatment response. However, these factors are important given the lower sustained virologic response (SVR) rates observed in black and Hispanic/Latino patients treated with PR. Goals: This retrospective pooled analysis evaluated the effect of race or ethnicity on treatment-naive patient response to telaprevir-based therapy and assessed resistant variant profiles. Materials and Methods: This analysis comprised patients enrolled in ADVANCE (N=363) and ILLUMINATE (N=540) who received 12 weeks of telaprevir in combination with PR followed by 12 or 36 weeks of PR alone and patients in ADVANCE (N=361) who received 48 weeks of PR alone. Race and ethnicity were self-reported and not mutually exclusive. Results: Higher SVR rates were observed with telaprevir-based therapy compared with PR in blacks [n=99 (62%) vs. n=28 (29%), respectively] and in Hispanics/Latinos [n=89 (72%) vs. n=38 (39%)]. The SVR was lower in telaprevir-treated blacks [n=99 (62%)] compared with nonblacks [n=791 (78%)] and in Hispanic/Latinos compared with non-Hispanics/Latinos [n=89 (72%) vs. n=801 (76%)]. Low discontinuation rates due to adverse events, including rash and anemia, were observed across subgroups. Resistance profiles were similar among the subgroups. Conclusions: Treatment-naive black and Hispanic/Latino patients with genotype 1 chronic hepatitis C virus infection may benefit from telaprevir-based therapy, an important finding given the lower SVR rates observed in these patients when they are treated with PR alone." @default.
• W2334985384 created "2016-06-24" @default.
• W2334985384 creator A5010156977 @default.
• W2334985384 creator A5035934475 @default.
• W2334985384 creator A5038073374 @default.
• W2334985384 creator A5038426997 @default.
• W2334985384 creator A5039066540 @default.
• W2334985384 creator A5040817770 @default.
• W2334985384 creator A5041578015 @default.
• W2334985384 creator A5052742729 @default.
• W2334985384 creator A5057269368 @default.
• W2334985384 creator A5068309561 @default.
• W2334985384 creator A5069782760 @default.
• W2334985384 creator A5073412832 @default.
• W2334985384 creator A5074779832 @default.
• W2334985384 creator A5082773746 @default.
• W2334985384 date "2015-04-01" @default.
• W2334985384 modified "2023-09-25" @default.
• W2334985384 title "Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity" @default.
• W2334985384 cites W1972228563 @default.
• W2334985384 cites W1984175031 @default.
• W2334985384 cites W1985654847 @default.
• W2334985384 cites W1993575761 @default.
• W2334985384 cites W1995724407 @default.
• W2334985384 cites W2000837109 @default.
• W2334985384 cites W2009693944 @default.
• W2334985384 cites W2018964760 @default.
• W2334985384 cites W2027545702 @default.
• W2334985384 cites W2040463160 @default.
• W2334985384 cites W2048196618 @default.
• W2334985384 cites W2060895146 @default.
• W2334985384 cites W2063285149 @default.
• W2334985384 cites W2094174828 @default.
• W2334985384 cites W2109413486 @default.
• W2334985384 cites W2112876622 @default.
• W2334985384 cites W2113450786 @default.
• W2334985384 cites W2114376411 @default.
• W2334985384 cites W2125963799 @default.
• W2334985384 cites W2127685726 @default.
• W2334985384 cites W2143559032 @default.
• W2334985384 cites W2168911689 @default.
• W2334985384 cites W2314619766 @default.
• W2334985384 doi "https://doi.org/10.1097/mcg.0000000000000150" @default.
• W2334985384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24828357" @default.
• W2334985384 hasPublicationYear "2015" @default.
• W2334985384 type Work @default.
• W2334985384 sameAs 2334985384 @default.
• W2334985384 citedByCount "8" @default.
• W2334985384 countsByYear W23349853842015 @default.
• W2334985384 countsByYear W23349853842016 @default.
• W2334985384 countsByYear W23349853842017 @default.
• W2334985384 countsByYear W23349853842018 @default.
• W2334985384 crossrefType "journal-article" @default.
• W2334985384 hasAuthorship W2334985384A5010156977 @default.
• W2334985384 hasAuthorship W2334985384A5035934475 @default.
• W2334985384 hasAuthorship W2334985384A5038073374 @default.
• W2334985384 hasAuthorship W2334985384A5038426997 @default.
• W2334985384 hasAuthorship W2334985384A5039066540 @default.
• W2334985384 hasAuthorship W2334985384A5040817770 @default.
• W2334985384 hasAuthorship W2334985384A5041578015 @default.
• W2334985384 hasAuthorship W2334985384A5052742729 @default.
• W2334985384 hasAuthorship W2334985384A5057269368 @default.
• W2334985384 hasAuthorship W2334985384A5068309561 @default.
• W2334985384 hasAuthorship W2334985384A5069782760 @default.
• W2334985384 hasAuthorship W2334985384A5073412832 @default.
• W2334985384 hasAuthorship W2334985384A5074779832 @default.
• W2334985384 hasAuthorship W2334985384A5082773746 @default.
• W2334985384 hasConcept C104317684 @default.
• W2334985384 hasConcept C126322002 @default.
• W2334985384 hasConcept C135763542 @default.
• W2334985384 hasConcept C137403100 @default.
• W2334985384 hasConcept C144024400 @default.
• W2334985384 hasConcept C185592680 @default.
• W2334985384 hasConcept C19165224 @default.
• W2334985384 hasConcept C197934379 @default.
• W2334985384 hasConcept C203014093 @default.
• W2334985384 hasConcept C2522874641 @default.
• W2334985384 hasConcept C2776408679 @default.
• W2334985384 hasConcept C2776455275 @default.
• W2334985384 hasConcept C2778159067 @default.
• W2334985384 hasConcept C2778715236 @default.
• W2334985384 hasConcept C2780040827 @default.
• W2334985384 hasConcept C55493867 @default.
• W2334985384 hasConcept C71924100 @default.
• W2334985384 hasConcept C90924648 @default.
• W2334985384 hasConceptScore W2334985384C104317684 @default.
• W2334985384 hasConceptScore W2334985384C126322002 @default.
• W2334985384 hasConceptScore W2334985384C135763542 @default.
• W2334985384 hasConceptScore W2334985384C137403100 @default.
• W2334985384 hasConceptScore W2334985384C144024400 @default.
• W2334985384 hasConceptScore W2334985384C185592680 @default.
• W2334985384 hasConceptScore W2334985384C19165224 @default.
• W2334985384 hasConceptScore W2334985384C197934379 @default.
• W2334985384 hasConceptScore W2334985384C203014093 @default.
• W2334985384 hasConceptScore W2334985384C2522874641 @default.
• W2334985384 hasConceptScore W2334985384C2776408679 @default.
• W2334985384 hasConceptScore W2334985384C2776455275 @default.
• W2334985384 hasConceptScore W2334985384C2778159067 @default.

• next